Peter McGranaghan1,2, Anshul Saxena2, Muni Rubens2, Jasmin Radenkovic1,3, Doris Bach1,3, Leonhard Schleußner1,3, Burkert Pieske1,3,4,5, Frank Edelmann1,3,4, Tobias Daniel Trippel1,3. 1. Department of Internal Medicine and Cardiology, Charité - Campus Virchow-Klinikum, Berlin, Germany. 2. Baptist Health South Florida, Coral Gables, FL, USA. 3. DZHK (German Centre for Cardiovascular Research), Berlin, Germany. 4. Berlin Institute of Health (BIH), Berlin, Germany. 5. Department of Internal Medicine and Cardiology, German Heart Center Berlin, Berlin, Germany.
Abstract
Background: Metabolomic analysis aids in the identification of novel biomarkers by revealing the metabolic dysregulations underlying cardiovascular disease (CVD) aetiology. The aim of this study was to evaluate which metabolic biomarkers could add value for the prognosis of CVD events using meta-analysis. Methods: The PRISMA guideline was followed for the systematic review. For the meta-analysis, biomarkers were included if they were tested in multivariate prediction models for fatal CVD outcomes. We grouped the metabolites in biological classes for subgroup analysis. We evaluated the prediction performance of models which reported discrimination and/or reclassification statistics. Results: For the systematic review, there were 22 studies which met the inclusion/exclusion criteria. For the meta-analysis, there were 41 metabolites grouped into 8 classes from 19 studies (45,420 subjects, 5954 events). A total of 39 of the 41 metabolites were significant with a combined effect size of 1.14 (1.07-1.20). For the predictive performance assessment, there were 21 studies, 54,337 subjects, 6415 events. The average change in c-statistic after adding the biomarkers to a clinical model was 0.0417 (SE 0.008).Conclusions: This study provides evidence that metabolomic biomarkers, mainly lipid species, have the potential to provide additional prognostic value. Current data are promising, although approaches and results are heterogeneous.
Background: Metabolomic analysis aids in the identification of novel biomarkers by revealing the metabolic dysregulations underlying cardiovascular disease (CVD) aetiology. The aim of this study was to evaluate which metabolic biomarkers could add value for the prognosis of CVD events using meta-analysis. Methods: The PRISMA guideline was followed for the systematic review. For the meta-analysis, biomarkers were included if they were tested in multivariate prediction models for fatal CVD outcomes. We grouped the metabolites in biological classes for subgroup analysis. We evaluated the prediction performance of models which reported discrimination and/or reclassification statistics. Results: For the systematic review, there were 22 studies which met the inclusion/exclusion criteria. For the meta-analysis, there were 41 metabolites grouped into 8 classes from 19 studies (45,420 subjects, 5954 events). A total of 39 of the 41 metabolites were significant with a combined effect size of 1.14 (1.07-1.20). For the predictive performance assessment, there were 21 studies, 54,337 subjects, 6415 events. The average change in c-statistic after adding the biomarkers to a clinical model was 0.0417 (SE 0.008).Conclusions: This study provides evidence that metabolomic biomarkers, mainly lipid species, have the potential to provide additional prognostic value. Current data are promising, although approaches and results are heterogeneous.
Authors: Raul Sanchez-Gimenez; Wahiba Ahmed-Khodja; Yesica Molina; Oscar M Peiró; Gil Bonet; Anna Carrasquer; George A Fragkiadakis; Mònica Bulló; Alfredo Bardaji; Christopher Papandreou Journal: Nutrients Date: 2022-06-27 Impact factor: 6.706
Authors: Peter McGranaghan; Jennifer A Kirwan; Mariel A Garcia-Rivera; Burkert Pieske; Frank Edelmann; Florian Blaschke; Sandeep Appunni; Anshul Saxena; Muni Rubens; Emir Veledar; Tobias Daniel Trippel Journal: Metabolites Date: 2021-09-14
Authors: Aline M A Martins; Mariana U B Paiva; Diego V N Paiva; Raphaela M de Oliveira; Henrique L Machado; Leonardo J S R Alves; Carolina R C Picossi; Andréa T Faccio; Marina F M Tavares; Coral Barbas; Viviane Z R Giraldez; Raul D Santos; Guilherme U Monte; Fernando A Atik Journal: Front Cardiovasc Med Date: 2021-12-22
Authors: Marta Galvez-Fernandez; Francisco Sanchez-Saez; Arce Domingo-Relloso; Zulema Rodriguez-Hernandez; Sonia Tarazona; Vannina Gonzalez-Marrachelli; Maria Grau-Perez; Jose M Morales-Tatay; Nuria Amigo; Tamara Garcia-Barrera; Jose L Gomez-Ariza; F Javier Chaves; Ana Barbara Garcia-Garcia; Rebeca Melero; Maria Tellez-Plaza; Juan C Martin-Escudero; Josep Redon; Daniel Monleon Journal: Redox Biol Date: 2022-04-14 Impact factor: 10.787
Authors: Ming Liu; Yiheng Huang; Hongwei Zhang; Dawn Aitken; Michael C Nevitt; Jason S Rockel; Jean-Pierre Pelletier; Cora E Lewis; James Torner; Yoga Raja Rampersaud; Anthony V Perruccio; Nizar N Mahomed; Andrew Furey; Edward W Randell; Proton Rahman; Guang Sun; Johanne Martel-Pelletier; Mohit Kapoor; Graeme Jones; David Felson; Dake Qi; Guangju Zhai Journal: Metabolites Date: 2022-04-07